Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow IMUX by emailGet an email when IMUX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IMUX, unsubscribe in one click. Privacy
📣 What IMUX Says Is Next
by the end of 2026 · “Anticipated Clinical Milestones · Vidofludimus Calcium in Relapsing MS: Top-line data from the twin Phase 3 ENSURE-1 and ENSURE-2 trials remains on track and is expected to be available by the end of 2026.”
Company press release, Aug 11, 2026 · SEC filing
by the end of 2026 · “We believe this approach has the potential to deliver meaningful efficacy while maintaining the favorable safety and tolerability profile observed to date, positioning vidofludimus calcium as a potentially important new oral treatment option for people living with MS.” “Our Phase 3 ENSURE trials of vidofludimus calcium in relapsing MS remain on track to report top-line data by the end of 2026,” added Michael A.”
Company press release, Aug 11, 2026 · SEC filing
in 2026 · “Initiation of an additional Phase 3 clinical trial in progressive MS is expected later in 2026.”
Company press release, Aug 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full IMUX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMUX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.